SCHMID, Christoph, Myriam LABOPIN, Arnon NAGLER, Dietger NIEDERWIESER, Luca CASTAGNA, Reza TABRIZI, Michael STADLER, Juergen KUBALL, Jan CORNELISSEN, Jiří VORLÍČEK, Gerard SOCIÉ, Michele FALDA, Lars VINDELOV, Per LJUNGMAN, Graham JACKSON, Nicolaus KROEGER, Andreas RANK, Emmanuelle POLGE, Vanderson ROCHA and Mohamad MOHTY. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood. Washington DC, USA: American Society of Hematology, 2012, vol. 119, No 6, p. 1599-1606. ISSN 0006-4971. doi:10.1182/blood-2011-08-375840.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation
Authors SCHMID, Christoph, Myriam LABOPIN, Arnon NAGLER, Dietger NIEDERWIESER, Luca CASTAGNA, Reza TABRIZI, Michael STADLER, Juergen KUBALL, Jan CORNELISSEN, Jiří VORLÍČEK, Gerard SOCIÉ, Michele FALDA, Lars VINDELOV, Per LJUNGMAN, Graham JACKSON, Nicolaus KROEGER, Andreas RANK, Emmanuelle POLGE, Vanderson ROCHA and Mohamad MOHTY.
Edition Blood, Washington DC, USA, American Society of Hematology, 2012, 0006-4971.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 9.060
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1182/blood-2011-08-375840
UT WoS 000300420900037
Keywords in English ACUTE MYELOID-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; 1ST INTERNATIONAL WORKSHOP; GRAFT-VERSUS-LEUKEMIA; LOW-DOSE AZACITIDINE; MYELODYSPLASTIC SYNDROMES; HEMATOLOGIC MALIGNANCIES; MYELOABLATIVE THERAPY; PATIENTS OLDER; WORKING PARTY
Tags International impact, Reviewed
Changed by Changed by: Ing. Mgr. Věra Pospíšilíková, učo 9005. Changed: 23/4/2014 15:10.
Abstract
Because information on management and outcome of AML relapse after allogeneic hematopoietic stem cell transplantation (HSCT) with reduced intensity conditioning (RIC) is scarce, a retrospective registry study was performed by the Acute Leukemia Working Party of EBMT. Among 2815 RIC transplants performed for AML in complete remission (CR) between 1999 and 2008, cumulative incidence of relapse was 32% +/- 1%. Relapsed patients (263) were included into a detailed analysis of risk factors for overall survival (OS) and building of a prognostic score. CR was reinduced in 32%; remission duration after transplantation was the only prognostic factor for response (P = .003). Estimated 2-year OS from relapse was 14%, thereby resembling results of AML relapse after standard conditioning. Among variables available at the time of relapse, remission after HSCT > 5 months (hazard ratio [HR] = 0.50, 95% confidence interval [CI], 0.37-0.67, P < .001), bone marrow blasts less than 27% (HR = 0.53, 95% CI, 0.40-0.72, P < .001), and absence of acute GVHD after HSCT (HR = 0.67, 95% CI, 0.49-0.93, P = .017) were associated with better OS. Based on these factors, 3 prognostic groups could be discriminated, showing OS of 32% +/- 7%, 19% +/- 4%, and 4% +/- 2% at 2 years (P < .0001). Long-term survival was achieved almost exclusively after successful induction of CR by cytoreductive therapy, followed either by donor lymphocyte infusion or second HSCT for consolidation.
PrintDisplayed: 22/10/2021 02:31